Tracking the Current Rise of Chinese Pharmaceutical Bionanotechnology

T. Lenoir, Patrick Herron
{"title":"Tracking the Current Rise of Chinese Pharmaceutical Bionanotechnology","authors":"T. Lenoir, Patrick Herron","doi":"10.5210/DISCO.V4I0.2491","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background: The Context and Purpose of the Study Over the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China’s scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the impact of Chinese policy on nanotechnology research production. Results, the main findings Our text mining-based methods provide results that counter existing claims about Chinese nanotechnology research quality. Due in large part to its strategic innovation policy, China’s output of nanotechnology publications is on pace to surpass US production in or around 2012.A closer look at Chinese nanotechnology research literature reveals a large increase in research activity in China’s biopharmananotechnology research since the implementation in January, 2006 of China’s Medium & Long Term Scientific and Technological Development Plan Guidelines for the period 2006-2020 (“MLP”). Since the implementation of the MLP, China has enjoyed a great deal of success producing bionano research findings while attracting a great deal of foreign investment from pharmaceutical corporations setting up advanced drug discovery operations. Given the combination of current scientific production growth as well as economic growth, a relatively low scientific capacity, and the ability of its policy to enhance such trends, China is in some sense already the new world leader in nanotechnology. Further, the Chinese national innovation system may be the new standard by which other national S&T policies should be measured.","PeriodicalId":87404,"journal":{"name":"Journal of biomedical discovery and collaboration","volume":"30 1","pages":"8 - 8"},"PeriodicalIF":0.0000,"publicationDate":"2009-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"25","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical discovery and collaboration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5210/DISCO.V4I0.2491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 25

Abstract

ABSTRACT Background: The Context and Purpose of the Study Over the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China’s scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the impact of Chinese policy on nanotechnology research production. Results, the main findings Our text mining-based methods provide results that counter existing claims about Chinese nanotechnology research quality. Due in large part to its strategic innovation policy, China’s output of nanotechnology publications is on pace to surpass US production in or around 2012.A closer look at Chinese nanotechnology research literature reveals a large increase in research activity in China’s biopharmananotechnology research since the implementation in January, 2006 of China’s Medium & Long Term Scientific and Technological Development Plan Guidelines for the period 2006-2020 (“MLP”). Since the implementation of the MLP, China has enjoyed a great deal of success producing bionano research findings while attracting a great deal of foreign investment from pharmaceutical corporations setting up advanced drug discovery operations. Given the combination of current scientific production growth as well as economic growth, a relatively low scientific capacity, and the ability of its policy to enhance such trends, China is in some sense already the new world leader in nanotechnology. Further, the Chinese national innovation system may be the new standard by which other national S&T policies should be measured.
跟踪当前中国制药生物纳米技术的崛起
摘要背景:本研究的背景和目的在过去十年中,中国已成为科学出版物的主要生产国,目前排名第二,仅次于美国。在此期间,中国的战略政策举措将自主创新置于其经济的核心,同时将内部研发投资和纳米技术吸引外国投资作为其四大领域之一。中国的科研出版物和纳米技术研究出版物产出量已达到世界第二位,仅次于美国。尽管取得了这些令人印象深刻的进步,但一些学者认为,由于总体被引用次数率较低,中国纳米技术研究的质量不如美国的研究质量,这表明美国仍然是世界领先者。我们结合引文分析、文本挖掘、地图绘制和数据可视化来衡量纳米技术在中国的发展和应用,特别是在生物制药技术方面,并衡量中国政策对纳米技术研究成果的影响。我们基于文本挖掘的方法提供的结果与现有的关于中国纳米技术研究质量的说法相反。在很大程度上,由于其战略创新政策,中国纳米技术出版物的产量有望在2012年左右超过美国。仔细研究中国的纳米技术研究文献就会发现,自2006年1月《中国中长期科学和技术发展规划纲要(2006-2020年)》实施以来,中国的生物制药技术研究活动大幅增加。自实施生物纳米计划以来,中国在生物纳米研究成果方面取得了巨大成功,同时吸引了大量外国制药公司的投资,建立了先进的药物发现业务。考虑到目前的科学生产增长和经济增长、相对较低的科学能力以及促进这种趋势的政策能力,中国在某种意义上已经是纳米技术领域新的世界领导者。此外,中国的国家创新体系可能成为衡量其他国家科技政策的新标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信